A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients
Key facts
- Who runs it
- University of Chicago
- Where
- Chicago, United StatesSee the site
- Trial code
- Status
- Terminated
- Phase
- Phase 1
- People taking part
- 60 people enrolled
- Started
- 13 Feb 2023
- Ended
- 5 Aug 2024
- Type of study
- Interventional, 5 groups
- Treatments tested
- Relugolix Pill
- Ritonavir
- Itraconazole
- Record updated
- 19 September 2024
- Why it stopped
- Terminated by the PI
Who can take part
- Age
- 18 years and older
- Sex
- Men only
- Healthy volunteers
- Cannot take part
Show the full registry criteria (17)Hide the full registry criteria
Who can take part
- Must have histologically or cytologically confirmed prostate cancer with plans to start medical castration therapy
- Age 18 or older. Because no dosing or adverse event data are currently available on the use of relugolix in combination with itraconazole or ritonavir in patients <18 years of age, children are excluded from this study
- Eastern Cooperative Oncology Group performance status ≤2 (Karnofsky ≥60%)
- Participants must satisfy the following laboratory criteria:
- Testosterone > 200 ng/dl
- QTc within normal limits
- Aspartate Transferase (AST)/alanine transaminase (ALT) < 3x upper limit of normal
- Ability to take oral medication and be willing to adhere to the medication regimen
- Ability to understand and the willingness to sign a written informed consent document
Who cannot take part
- Concurrent therapy with strong interacting drugs with CYP3A4 and P-gp (See Appendix list of strong inhibitors or inducers) due to concerning possible drug-drug interactions with itraconazole, ritonavir and relugolix. Potential drug-drug interactions will also be reviewed by study investigators prior to enrollment
- Patients receiving treatment with another investigational drug or other intervention within 3 expected half-lives of the agent
- Need for combination systemic therapy for prostate cancer including docetaxel and/or second-generation androgen receptor pathway targeted agents (i.e. abiraterone, enzalutamide, apalutamide, darolutamide, etc)
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to relugolix, itraconazole or ritonavir
- Serious or uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, unstable angina pectoris, or psychiatric illness/social situations that would limit compliance with study requirements
- New York Heart Association Class III of IV congestive heart failure
- Active psychiatric illness/social situations that would limit compliance with protocol requirements
- Known gastrointestinal malabsorption
Where in United States
- University of Chicago Comprehensive Cancer CenterChicago, United States
About the trial
What the trial wants to find out
Researchers leading this study hope to learn about the safety of combining the study drug relugolix with another study drug called itraconazole or ritonavir in prostate cancer. This study is for individuals who have advanced prostate cancer and plans to have medical castration (the use of medications or chemicals to lower hormone production in the testicles). Your participation in this research will last up to 1 month.
Read full original descriptionShow less
The purpose of this research is to gather information on the safety and effectiveness of relugolix in combination with ritonavir or itraconazole. The goal of this research is to find out if combining two medications (relugolix and itraconazole or relugolix and ritonavir) could possibly lead to using less relugolix, which is an expensive drug.
The 5 groups in the trial
- Study Group 1Treatment being tested
All study participants will receive a starting dose of relugolix (360 mg in the form of three 120 mg tablets) on Day 1 of the 29-day drug administration period. After Day 1, you will receive relugolix on its own or relugolix combined with another medication called itraconazole or ritonavir. The combination of medications you receive, the dosage for each medication, and when you take each medication will be based on the study group you are enrolled in. Study Group 1 will receive: * Relugolix (360 mg) on Day 1 * Relugolix (120 mg) on Days 2-7
Treatment: Relugolix Pill
- Study Group 2aTreatment being tested
All study participants will receive a starting dose of relugolix (360 mg in the form of three 120 mg tablets) on Day 1 of the 29-day drug administration period. After Day 1, you will receive relugolix on its own or relugolix combined with another medication called itraconazole or ritonavir. The combination of medications you receive, the dosage for each medication, and when you take each medication will be based on the study group you are enrolled in. Study Group 2a will receive: * Relugolix (360 mg) on Day 1 * Relugolix (120 mg) on Days 2-7 * Itraconazole (200 mg) on Days 1-14
Treatment: Relugolix Pill and Itraconazole
- Study Group 2bTreatment being tested
All study participants will receive a starting dose of relugolix (360 mg in the form of three 120 mg tablets) on Day 1 of the 29-day drug administration period. After Day 1, you will receive relugolix on its own or relugolix combined with another medication called itraconazole or ritonavir. The combination of medications you receive, the dosage for each medication, and when you take each medication will be based on the study group you are enrolled in. Study Group 2b will receive: * Relugolix (360 mg) on Day 1 * Relugolix (120 mg) on Days 2-7 * Ritonavir (100 mg tablets taken by mouth) on Days 1-14
Treatment: Relugolix Pill and Ritonavir
- Study Group 3aTreatment being tested
All study participants will receive a starting dose of relugolix (360 mg in the form of three 120 mg tablets) on Day 1 of the 29-day drug administration period. After Day 1, you will receive relugolix on its own or relugolix combined with another medication called itraconazole or ritonavir. The combination of medications you receive, the dosage for each medication, and when you take each medication will be based on the study group you are enrolled in. Study Group 3a will receive: * Relugolix (360 mg) on Day 1 * Relugolix (120 mg) on Days 2-4 * Itraconazole (200 mg tablets taken by mouth) on Days 1-14
Treatment: Relugolix Pill and Itraconazole
- Study Group 3bTreatment being tested
All study participants will receive a starting dose of relugolix (360 mg in the form of three 120 mg tablets) on Day 1 of the 29-day drug administration period. After Day 1, you will receive relugolix on its own or relugolix combined with another medication called itraconazole or ritonavir. The combination of medications you receive, the dosage for each medication, and when you take each medication will be based on the study group you are enrolled in. Study Group 3b will receive: * Relugolix (360 mg) on Day 1 * Relugolix (120 mg) on Days 2-4 * Ritonavir (100 mg) on Days 1-14
Treatment: Relugolix Pill and Ritonavir
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase Ib Study of Extending Relugolix Dosing Intervals Through Addition of the CYP3A4 and Pg-P Inhibitor Itraconazole or Ritonavir in Prostate Cancer Patients
- Record updated
- 19 September 2024